| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
A team of researchers has confirmed that neutralizing monoclonal antibody (nMAb) therapies are associated with reduced risk of adverse outcomes of COVID-19 in high-risk populations. The cohort study, published in JAMA, included more than 167,000 nonhospitalized patients from health care systems based in California, Texas, and Utah, and at Mayo Clinic in Rochester, Minnesota.
In May 2023, Mayo Clinic Laboratories announced 22 new tests along with numerous reference value changes, obsolete tests, and algorithm changes.
Due to the Memorial Day holiday (recognized on Monday, May 29), Mayo Clinic Laboratories' specimen pickup and delivery schedules will be altered. To ensure that your specimen vitality and turnaround times are not affected, please plan ahead.
Visit Mayo Clinic Laboratories at booth #2047 to learn about our comprehensive therapeutics test offerings. Developed by board-certified experts in clinical chemistry, molecular, and toxicology testing, our testing is designed to detect and monitor therapeutic and illicit drugs across several relevant specimen types.
In April 2023, Mayo Clinic Laboratories announced 10 new tests along with numerous reference value changes, obsolete tests, and algorithm changes.
A medical mystery surrounding a clotting disease spurred a collaboration between Mayo Clinic and University of Michigan Health to develop a new test methodology and the discovery of a previously unknown blood clotting condition.
Top highlights include: US adult cigarette smoking rate hits new all-time low, ongoing search for long COVID treatment continues, and scientists try to understand the impact of social media on teens.
A specific type of fungal species, Candida auris, is raising concern in health care facilities around the world. First discovered in Japan in 2009, Candida auris is responsible for an increasing number of serious and often fatal fungal infections. Nancy Wengenack, Ph.D., director of the Mycology and Mycobacteriology Laboratories at Mayo Clinic Laboratories, explains why these infections are difficult to treat.
Thank you to all laboratory professionals for their efforts to provide critical answers for patients every day, and drive innovation in the field of medicine.
Top highlights include: Millions expected to lose dental care coverage, overdose deaths of elderly on the rise, and Minnesota Health Department urges caution for well owners as flood waters rise.
Matthew Binnicker, Ph.D., director of Mayo Clinic’s Clinical Virology Laboratory, provides insight on the newest COVID-19 subvariant – XBB.1.16, also known as “Arcturus.”
Matthew Binnicker, Ph.D., director of Mayo Clinic’s Clinical Virology Laboratory, provides an update on the ongoing global avian influenza outbreak and what’s being done to prepare for a potential human-to-human outbreak.
Top highlights include: Adderall shortage is taking a toll, scientists are reconsidering the dangers of prospecting for unknown viruses, and can community paramedcine improve health outcomes in rural America?